MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study

MedAlliance has announced enrollment of over 1,660 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now half way towards a planned 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon (SELUTION SLR), versus any limus drug-eluting stent (DES). SELUTION DeNovo is the largest DEB study ever initiated, […]

thaipr.net

15 ก.ย. 66

Variants in the genome interact with each other and with the environment to affect risk of cardiovascular disease

Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare system and The Copenhagen University, publish a study today in the journal Cell titled “Complex effects of sequence variants on lipid levels and coronary artery disease”. The work described in the paper is based on searching for variants in the genome […]

thaipr.net

15 ก.ย. 66

91% of doctors in Southeast Asia participate in digital learning despite societal return to in-person interactions – Docquity

Despite a societal return to in-person interactions, 91.1% of Southeast Asia’s doctors continue to participate in digital learning events, according to the newly published Docquity Pulse Check 2023: Decoding a Doctor’s Learning and Engagement Habits. The study showed that the region’s doctors attend digital learning events at a higher rate (3.9 times per month) compared to in-person […]

thaipr.net

14 ก.ย. 66

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 mg Tablets (generic name: peficitinib hydrobromide) in Taiwan for the treatment of rheumatoid arthritis. Smyraf® has been approved in Taiwan and […]

thaipr.net

13 ก.ย. 66

CSafe Expands Executive Team with Chief Financial Officer

Seasoned financial leader, Anthony Pishotti, joins CSafe executive team to further drive the company’s portfolio and geographic growth. CSafe, the largest active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, announced today that Anthony Pishotti has joined the team as Chief Financial Officer (CFO). This expansion of the executive leadership team will accelerate […]

thaipr.net

13 ก.ย. 66

Waters Launches New Walk-up Solutions that Further Simplify the Analysis of Biologic Drug Product and Cell Culture Media

News Summary: Waters Corporation (WAT:NYSE) announced new bioprocess walk-up solutions designed to further simplify biologic sample prep and analysis. By eliminating the need to send bioreactor samples to a central laboratory for analysis, the new solutions make it even easier to accelerate upstream bioprocess development by up to six weeks over traditional methods.i Enabled by updates […]

thaipr.net

13 ก.ย. 66

Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer

Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment of Saulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience and a unique blend of leadership, operational expertise, and a deep understanding of manufacturing operational excellence and supply […]

thaipr.net

11 ก.ย. 66

MedAlliance announces enrollment of First Patient in SELUTION SLR LOVE-DEB Coronary Study

The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease treated with SELUTION SLR™. This is a trial initiated by physicians at the Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, which is where the first patient was enrolled. SELUTION SLR is a novel sirolimus-eluting balloon that provides […]

thaipr.net

11 ก.ย. 66

PeproMene Bio, Inc. Announced Completion of the First Dose Cohort and Opening of the Second Dose Cohort in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells)

PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first dose cohort of its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) clinical trial of PMB-CT01 (BAFFR-CAR T Cells) has been completed. No Dose Limiting Toxicity (DLT) was observed, and the study […]

thaipr.net

11 ก.ย. 66
1 29 30 31 32 33 128